Henlius and Ascentage Pharma Collaborate to Evaluate the Combination Therapy for Chronic Lymphocytic Leukemia in China

Henlius and Ascentage Pharma Collaborate to Evaluate the Combination Therapy for Chronic Lymphocytic Leukemia in China

Shots:

  • The companies collaborated to conduct the clinical studies of a dual regimen consisting of Ascentage’s APG-2575 and Henlius’s HLX01 (biosimilar, rituximab) for the treatment of chronic lymphocytic leukemia in the People’s Republic of China
  • The teams from both the companies will explore the clinical utility of the dual regimen aiming to demonstrate a synergistic effect in the treatment of CLL, offering an additional treatment option to patients in China
  • Ascentage’s APG-2575 is a Bcl-2 selective inhibitor, act by restoring apoptosis process in cancer cells while Henlius’s HLX01 is the first approved biosimilar in China indicated to treat non-Hodgkin’s lymphoma

Click here to­ read full press release/ article | Ref: PRnewswire | Image: Yahoo News Singapore